Asset Details
Do you wish to reserve the book?
Comparative Effectiveness Questions in Oncology
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparative Effectiveness Questions in Oncology
Do you wish to request the book?
Comparative Effectiveness Questions in Oncology
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparative Effectiveness Questions in Oncology
2014
Overview
High prices for cancer drugs preclude independent comparative effectiveness trials that would seek to establish equally effective but cheaper alternatives — thereby protecting the market share of expensive drugs. How can we make progress toward conducting such trials?
The high cost of cancer drugs has been criticized by leading academics
1
and lamented in the popular press.
2
The average price of 1 year of treatment with a new cancer drug now exceeds $100,000,
1
and the benefits of many of these therapies — often improvement in median survival on the order of weeks to months — do not appear commensurate with their prices.
2
Expensive cancer drugs cost society in two ways. First, high prices are borne by payers each time these drugs are prescribed. And second, high prices preclude independent comparative effectiveness trials that would seek to establish equally effective . . .
Publisher
Massachusetts Medical Society
